OTCMKTS:KHTRF

Knight Therapeutics - KHTRF Stock Forecast, Price & News

$3.90

0.00 (0.00%)

(As of 02/7/2023 12:00 AM ET)

Add

Compare

Today's Range: $3.90
▼
$3.90
50-Day Range: $3.80
▼
$4.06
52-Week Range: $3.79
▼
$4.77

Volume: N/A
Average Volume: 2,445 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.55

About Knight Therapeutics (OTCMKTS:KHTRF) Stock

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Stock News Headlines

January 26, 2023 | finance.yahoo.com

Berkadia Forges Alliance With Knight Frank

December 23, 2022 | marketwatch.com

Knight Therapeutics Closes $38.5 Mln Loan With International Finance Corp.

February 7, 2023 | Wall Street Watch Dogs (Ad)

A gold storm is coming…

“We are in the early stages of a mania – the calm before the storm.”...

December 23, 2022 | finance.yahoo.com

Knight Therapeutics Closes US$38.5 million Loan with IFC

November 13, 2022 | seekingalpha.com

Knight Therapeutics Inc. (KHTRF) Q3 2022 Earnings Call Transcript

November 12, 2022 | finance.yahoo.com

Knight Therapeutics Third Quarter 2022 Earnings: Beats Expectations

November 9, 2022 | finance.yahoo.com

Knight to Present at Stifel Healthcare Conference

November 3, 2022 | finance.yahoo.com

Notice of Knight Therapeutics' Third Quarter 2022 Results Conference Call

February 7, 2023 | Wall Street Watch Dogs (Ad)

The #1 Energy Stock to Buy

The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…

August 12, 2022 | seekingalpha.com

Knight Therapeutics' (KHTRF) CEO Samira Sakhia on Q2 2022 Results - Earnings Call Transcript

August 12, 2022 | benzinga.com

G2S2 CAPITAL INC. FILES EARLY WARNING REPORT FOR INVESTMENT IN KNIGHT THERAPEUTICS INC.

July 4, 2022 | nasdaq.com

Knight Therapeutics To Relaunch AKYNZEO In Brazil

June 14, 2022 | finance.yahoo.com

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 24, 2022 | seekingalpha.com

Knight Therapeutics enters license, supply pacts with Rigel

May 12, 2022 | finance.yahoo.com

Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®

March 31, 2022 | finance.yahoo.com

Knight Therapeutics Inc. (TSE:GUD) insiders placed bullish bets worth CA$3.1m in the last 12 months

March 25, 2022 | seekingalpha.com

Knight Therapeutics reports Q4 results

March 17, 2022 | finance.yahoo.com

Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call

January 7, 2022 | nasdaq.com

Knight Therapeutics Inc (KHTRF)

December 14, 2021 | finance.yahoo.com

Is Knight Therapeutics (TSE:GUD) Using Too Much Debt?

December 2, 2021 | finance.yahoo.com

Knight to Present at Stifel GMP’s The Future of Healthcare Conference

November 11, 2021 | finance.yahoo.com

Knight Therapeutics Reports Third Quarter 2021

September 30, 2021 | finance.yahoo.com

What Type Of Shareholders Make Up Knight Therapeutics Inc.'s (TSE:GUD) Share Registry?

September 24, 2021 | finance.yahoo.com

Knight Therapeutics Inc. places No. 27 on The Globe and Mail’s third-annual ranking of Canada’s Top Growing Companies

September 23, 2021 | msn.com

BRIEF-Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With Incyte

August 13, 2021 | markets.businessinsider.com

What Wall Street expects from Knight Therapeutics's earnings

August 13, 2021 | finance.yahoo.com

Knight Therapeutics Reports Second Quarter 2021

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Company Calendar

Today: 2/07/2023
Next Earnings (Estimated): 3/22/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:KHTRF
CUSIP: N/A
CIK: N/A
Web: www.gud-knight.com
Phone: (514) 484-4483
Fax: N/A
Employees: 660
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.55
High Stock Price Forecast: $7.50
Low Stock Price Forecast: $5.40
Forecasted Upside/Downside: +67.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Samira Sakhia
President, Chief Executive Officer & Director

Utchanah Arvind
Chief Financial Officer

Monica Percario
Vice President-Global Scientific Affairs

Daniela Marino Marino
Vice President-Legal and Compliance

Amal Khouri
Chief Business Officer

Key Competitors

View All Competitors

KHTRF Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KHTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KHTRF, but not buy additional shares or sell existing shares.
View KHTRF analyst ratings or view top-rated stocks.
What is Knight Therapeutics' stock price forecast for 2023?: 1 brokers have issued 12-month price objectives for Knight Therapeutics' shares. Their KHTRF share price forecasts range from $5.40 to $7.50. On average, they expect the company's stock price to reach $6.55 in the next year. This suggests a possible upside of 67.9% from the stock's current price.
View analysts price targets for KHTRF or view top-rated stocks among Wall Street analysts.
How have KHTRF shares performed in 2023?: Knight Therapeutics' stock was trading at $3.80 at the beginning of the year. Since then, KHTRF shares have increased by 2.6% and is now trading at $3.90.
View the best growth stocks for 2023 here.
Are investors shorting Knight Therapeutics?: Knight Therapeutics saw a decline in short interest in January. As of January 15th, there was short interest totaling 451,300 shares, a decline of 12.5% from the December 31st total of 515,700 shares. Based on an average trading volume of 2,800 shares, the days-to-cover ratio is presently 161.2 days.
View Knight Therapeutics' Short Interest.

When is Knight Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our KHTRF earnings forecast.
What is Knight Therapeutics' stock symbol?: Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."
How do I buy shares of Knight Therapeutics?: Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Knight Therapeutics' stock price today?: One share of KHTRF stock can currently be purchased for approximately $3.90.
How many employees does Knight Therapeutics have?: The company employs 660 workers across the globe.
How can I contact Knight Therapeutics?: Knight Therapeutics' mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The official website for the company is www.gud-knight.com. The company can be reached via phone at (514) 484-4483.

This page (OTCMKTS:KHTRF) was last updated on 2/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial